Dabrafenib and trametinib: a drug combinations to treat metastatic
Dr Georgina Long from Westmead Hospital and the Melanoma Institute Australia and colleagues report that combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in progression-free survival, response rate and duration of response in 162 patients with melanoma that had BRAF V600 mutations. Patients in the study received either dabrafenib 150mg twice daily;